Fetal and Neonatal Monitoring Market - Restraints
The major restraining factor for the fetal and neonatal monitoring market include product recalls by the regulatory bodies. The product recalls arise due to product failure, component inconsistency, and packaging problems. For instance, in October 2019, the U.S. FDA recalled the Mindray DS USA, Inc.’s (a subsidiary of Mindray Medical International Limited) Rosie4 Vital Signs Monitor, which is used for monitoring physiologic parameters, including Pulse Oximetry (SpO2), Pulse Rate (PR), Non-invasive Blood Pressure (NIBP), Temperature (TEMP), and Carbon Dioxide (CO2) on adult, pediatric, and neonatal patients in professional healthcare facilities. The product was recalled by the U.S. FDA because the NIBM valve system was not included in the marketing clearance. The company initiated the recall but not all products were corrected or removed.
Fetal and Neonatal Monitoring Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients